Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to year-end report January-December 2023 for Truecaller AB (publ)

Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, is publishing its interim report for January-December on Tuesday 20 February 2024 at 07.30 CET.Alan Mamedi, CEO and Odd Bolin, CFO presents the report and answers questions in a webcast and conference call at 13.00 CET the same day. The presentation will be held in English.   If you wish to participate via webcast please use the link below.https://ir.financialhearings.com/truecaller-q4-report-2023/register  If you wish to participate via teleconference please register on the link

Wärtsilä to deliver ammonia fuel system for two EXMAR Medium size Gas Carriers

Wärtsilä Corporation, Press release, 8 February 10.30 AM EETWärtsilä Gas Solutions, part of technology group Wärtsilä, will deliver the fuel supply system for two new gas carriers that will operate with ammonia fuel . The ships are being built at the Hyundai Mipo Dockyards (HMD) in Korea for ship owner EXMAR LPG, a joint venture between Exmar, a multi-disciplinary maritime and offshore solutions provider, and Seapeak, one of the largest independent owner-operators of liquefied natural gas vessels. These EXMAR Medium size Gas Carriers new-

Axactor ASA: Invitation to presentation of Q4 2023 results

Axactor ASA will publish its fourth quarter 2023 results on Thursday 15February 2024. 07:00 am CET: The report and presentation will bemade available on axactor.com and newsweb.oslobors.no. 10:00 am CET: The results will be presented in a globalinvestor webcast with a live Q&A session. A recording of the webcast will bemade available after the live stream is concluded on axactor.com. Webcast participation will be possible via the following: Streaming- https://eu-app.webinar.net/paxw9o13K7g Phone- Dial-in pin: 885660- Norway: +47 81 50 33 08- Sweden: +46 10 884

Developing alternatives to palm oil with Getinge bioreactors

Getinge has entered a collaboration with NoPalm Ingredients in the Netherlands. The company will begin using Getinge’s bioreactors in their efforts to develop local, circular, and sustainable alternatives to palm oil. Ranging from small to larger volume cultivation systems, Getinge’s bioreactors will be key enablers in NoPalm Ingredients’ ambitions to upscale tests covering various feedstocks and applications. “We believe that this partnership will not only benefit our company but will also contribute to the broader scientific community by facilitating groundbreaking

K-Prefab to deliver frames for new construction at LV6 in Halmstad

K-Prefab AB, a subsidiary of K-Fast Holding AB (“K-Fastigheter”), has signed an agreement with NCC regarding delivery of concrete and steel frame solutions for new training and storage facilities at the Air Defense Regiment, LV6, in Halmstad. End customer for NCC is the Swedish Fortifications Agency. K-Prefab will deliver frame solutions including construction for two buildings, of which the largest covers 24,000 square meters. The premises will contain, among other things, halls for trucks and maintenance, special areas for theory and simulator training, auditorium, offices, changing

US-based company Enavate has chosen DecideAct for its strategy management

DecideAct has signed a contract with Enavate, a market-leading technology provider of business-transforming solutions for ERP, managed IT services, and cloud deployments for customers in Europe and the US. Enavate will use DecideAct's digital platform to manage the company's own strategic initiatives and sustainability objectives.Headquartered in Tampa, Florida, Enavate was founded in 2014 and is a leading technology provider that transforms businesses and the lives they touch with solutions including ERP, managed IT services, and cloud implementations. The company's consulting, cloud, and

Saab on CDP’s prestigious A list for climate change efforts

Saab has been recognised for leadership in corporate transparency and performance on climate change by the global environmental non-profit organisation CDP, securing a place on its annual ‘A list’.Saab is taking part in the global efforts to reduce carbon emissions and ensure long-term competitiveness. As a result, Saab is one of only a few companies world-wide that received an A grade in the climate change category of CDP’s list. As the first major defence company to have its science-based targets approved in December 2022, Saab is now delivering on them. "Combatting climate change

Invitation to presentation of Q4 and full year 2023 financial results

Viaplay Group will publish its Q4 and full year 2023 financial results at 07:30 CET on Thursday 22 February. A conference call will be held at 09:00 CET on Thursday 22 February with presentations from Jørgen Madsen Lindemann, Viaplay Group President and CEO, and Enrique Patrickson, Viaplay Group Chief Financial Officer. The call will be hosted by Matthew Hooper, Viaplay Group Chief Corporate Affairs Officer, and a question-and-answer session will follow the presentations.   OnlineTo view slides and listen to the conference call online use the following link, where questions can also

Lehto Group Plc, inside information: Subsidiaries of Lehto, Lehto Asunnot Oy, Lehto Tilat Oy and Lehto Korjausrakentaminen Oy have been declared bankrupt

Lehto Group PlcInsider information8 February 2024 at 9.45 a.m. (Finnish time)The operative subsidiaries of Lehto Group Oyj, Lehto Asunnot Oy, Lehto Tilat Oy and Lehto Korjausrakentaminen Oy, have filed bankruptcy applications on 6 February 2024. The District Court of Oulu has, by decision of 8 February 2024 at 9.00 a.m., declared Lehto Asunnot Oy, Lehto Tilat Oy and Lehto Korjausrakentaminen Oy bankrupt. District Court of Oulu has appointed attorney Antti Latola from Norra Attorneys Ltd to be the administrator of bankruptcy estates of Lehto Asunnot Oy, Lehto Tilat Oy and Lehto

NORDEN initiates share buy-back programme

ANNOUNCEMENT NO. 30 - 8 FEBRUAR 2024 The Board of Directors has decided to carry out a share buy-back of  up to a total of USD 15 million (approximately DKK 105 million). The share buy-back programme is initiated pursuant to the authorisation granted to the Board of Directors, which entitles NORDEN to acquire treasury shares at a nominal value not exceeding 10% of the share capital at the market price applicable at the time of acquisition with a deviation of up to 10%. This authorisation was granted at NORDEN’s general meeting on 9 March 2023.   Purpose The purpose of the share

Year-end report 2023

Fourth Quarter (Oct–Dec 2023) Net sales amounted to TSEK 161,868 (127,545), which is an increase of 26.9 % compared to the same period last year. The gross margin amounted to 51.9 % (58.3). Operating profit before depreciation (EBITDA) amounted to TSEK 44,520 (35,510), which corresponds to an operating margin before depreciation of 27.5 % (27.8). Operating profit (EBIT) amounted to TSEK 29,325 (24,369), which corresponds to an operating margin of 18.1 % (19.1). Earnings per share before dilution amounted to SEK 2.01 (1.76).(Comparative figures in parentheses refer to the

Himalaya Shipping Ltd. (HSHP) – Commercial Update and Key Information Relating to the Cash Distribution for January 2024

Hamilton, Bermuda, February 8, 2024 Commercial update: In January 2024, the Company achieved average time charter equivalent (“TCE”) earnings of approximately US$28,400 per day, gross[1]. The Company’s six vessels trading on a fixed time charter earned US$28,600 per day, gross, including average daily scrubber and LNG benefits on five vessels of approximately $2,800 per day. The Company’s three vessels trading on index-linked time charters earned approximately US$28,000 per day, gross, including average daily scrubber and LNG benefits of approximately US$3,000 per day. The index

The subscription price for the exercise of warrants of series TO3 in Pharmacolog has been set at SEK 0.054 per share

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Pharmacolog in Uppsala AB (“Pharmacolog” or “the Company”) completed a rights issue of units on the Nasdaq First North Growth Market in July 2023. Each unit consisted of four (4) series B shares and four (4) warrants of

Cloudberry Clean Energy ASA | CFO appointed

Oslo, Norway, 08 February 2024: Cloudberry Clean Energy ASA (Cloudberry) has today appointed Ole-Kristofer Bragnes as Chief Financial Officer (CFO). Former Chief Value Officer (CFO) Christian Helland will continue in Cloudberry as the Chief Commercial Officer (CCO) with an increased focus on value creation for the group.  Helland will as CCO lead Cloudberry’s commercial, M&A and new technologies segment.Bragnes currently serves as the Senior Financial Officer in Cloudberry, and he has over seven years of experience with capital markets transactions, debt structuring and other senior

Invitation to presentation of Storskogen’s year-end report 2023

On 15 February 2024 at 07:00 (CET), Storskogen announces its year-end report 2023. In connection with the announcement, a presentation will be held by Daniel Kaplan, CEO, and Lena Glader, CFO, followed by a Q&A session. The presentation will be held in English and starts at 09:00 (CET).The presentation and the subsequent Q&A can be followed via webcast or telephone conference. For participation via webcast, please use the following link:https://ir.financialhearings.com/storskogen-group-q4-report-2023/register If you wish to participate via telephone conference, please register via

Sleep Cycle year-end report 2023: Continued subscription growth sums up a strong full year

Gothenburg, Sweden — 8 February, 2024The fourth quarter in summary (October-December 2023) · Net sales totaled tSEK 61,254 (55,405) and increased by 10.6% (16.1%). Currency-adjusted net sales growth amounted to 5.7% (8.6%). · Operating profit amounted to tSEK 12,689 (4,549), with an operating margin of 20.7% (8.2%). Operating profit was affected by a non-cash impairment loss of tSEK 6,341. Excluding impairment, the margin was 31.1%. · Adjusted operating profit totaled tSEK 12,689 (7,351) and adjusted operating margin was 20.7% (13.3%). · The total number of paying subscribers

The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch

RaySearch Laboratories AB (publ) is proud to announce that The Royal Marsden NHS Foundation Trust, a specialist cancer center in the UK, will be the first in the world to implement online adaptive radiation therapy (OART) with RaySearch’s treatment planning system RayStation®* and oncology information system RayCare®* – including the new ARTemis* OART solution under development – in combination with the Radixact® Treatment Delivery System from Accuray.The Royal Marsden is at the forefront of radiotherapy research in the UK and globally and has been using RayStation for conventional

ExpreS2ion announces financial results for the fourth quarter and full-year 2023

Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments: “2023 unfolded in ways we had not anticipated, primarily due to a challenging funding environment and developments in our pipeline outside our control. However, we have commenced 2024 equipped with a clear, new strategic direction, a streamlined company, and a solid Phase III

Year-end report 2023 – Pricer AB

High net sales of 801 MSEK – an increase of 15 percent compared to last year.Fourth quarter 2023 • Net sales amounted to SEK 800.6 M (696.1), an increase of 15.0 percent compared to the same period last year. • Of net sales, SEK 17.5 M (11.9) refers to recurring revenue. • Gross margin amounted to 17.7 percent (15.5). • Operating profit (EBIT) amounted to SEK 20.1 M (27.9), which corresponds to an operating margin of 2.5 percent (4.0). • The company initiates a cost-saving program that is burdening the quarter with SEK 19.3 M in restructuring costs and SEK 14.8 M for

Attendo's year-end and fourth quarter report for 2023 to be published on 8 February - Invitation to presentation (NEW LINK)

On 8 February 2024 around 08:00 am (CET), Attendo will present its fourth quarter report for 2023. A webcast presentation will be held at 11:00 am (CET) on the same day.The presentation will be hosted by Attendo’s CEO Martin Tivéus and CFO Mikael Malmgren. The presentation will be held in English.   You can follow the presentation on the following page:https://ir.financialhearings.com/attendo-q4-report-2023   Analysts and investors will have the opportunity to ask questions during the presentation by calling in. To obtain call-in details, please send your request to:

XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event

XNK Therapeutics AB ("XNK”) today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.XNK’s presentation starts at 10:45 CET. The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye’s homepage. XNK’s presentation will be followed by a short Q&A session. For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail: johan.liwing@xnktherapeutics.com About XNK Therapeutics AB XNK Therapeutics is a clinical stage immunotherapy

BioStock: Deep dive into SynAct Pharma’s new strategy

With support from leading rheumatologists, SynAct Pharma is presenting a reshaped strategic plan for resomelagon in rheumatoid arthritis. In addition, they are planning to initiate a phase II trial with resomelagon in influenza patients and prepare the melanocortin agonist TXP-11 for clinical development. BioStock reached out to CEO Torbjørn Bjerke to learn more about the new strategic plan.Read the full article at biostock.se : https://www.biostock.se/en/2024/02/deep-dive-into-synact-pharmas-new-strategy/ This is a press release from BioStock - Connecting

NORDEN reports annual result of USD 400 million for 2023 and continues to return cash to shareholders

ANNOUNCEMENT NO. 29 - 8 FEBRUARY 2024 NORDEN reports an annual result of USD 400 million (approx. DKK 2,760 million). For the fourth quarter of 2023 net profit amounted to USD 43 million (approx. DKK 297 million).Freight Services & Trading posted a net profit of USD 133 million (approx. DKK 918 million) and Assets & Logistics a net profit of USD 268 million (approx. DKK 1,850 million) for the full-year 2023.     Free cashflow for the full-year 2023 amounted to USD 264 million (approx. DKK 1,822 million) and with a positive free cashflow of USD 30 million (DKK 207 million) for the

Rototilt’s joysticks win award again – winner of the “Good Design Award”

With two design awards in 2022 and a German Design Award in 2023, RC Joysticks from Rototilt have secured another win, this time receiving a Good Design Award in the “Electronics” category. “It was a meticulous design process, and we’re glad to see the appreciation, both in terms of the response from users and the industry,” says Caroline Jonsson, Product Manager at Rototilt.Rototilt, a Swedish tiltrotator manufacturer with subsidiaries worldwide, including North America, released the new joysticks for excavators and tiltrotators, RC Joysticks, in late 2022. Since then, they have won three

There are no items matching the current filter
There are no more items matching the current filter
Back to top